Zacks Analyst Blog Features Walmart, Adobe, Bristol-Myers Squibb Company, BHP Group and Micron Technology


For immediate release

Chicago, IL – April 1, 2022 – announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Walmart Inc. WMT, Adobe Inc. ADBE, Bristol-Myers Squibb Company BMY, BHP Group Ltd. BHP and Micron Technology, Inc. MU.

Here are highlights from Thursday’s analyst blog:

Best Stock Reports for Walmart, Adobe and Bristol Myers

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Walmart Inc., Adobe Inc. and Bristol-Myers Squibb Company. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.

You can see all today’s research reports here >>>

walmart shares have lagged the industry Zacks Retail – Supermarkets over the past year (+12.2% vs. +15.4%), reflecting the company’s high costs related to the retail chain. procurement, wages and COVID-19 weighing on the outlook for margins. The company expects operating profit and earnings per share to decline in the first quarter as it cycles the stimulus gains seen last year, as well as higher salaries for this year.

Walmart continues to benefit from its robust omnichannel efforts and last-mile delivery capabilities. With more customers and members returning to stores and clubs, demand appears to be strong. The reflection of the same was visible in the fourth quarter results, in which both the top and bottom results increased year over year.

(You can read the full Walmart research report here >>>)

Adobe shares have gained +52.8% over the past two periods against the industry’s +91% gain Zacks Computer – Software. The Zacks analyst believes the company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products drove revenue growth. In addition, rising subscription revenue and strong mobile app momentum remained key positives. Growth in emerging markets, strong demand for online video creation, and solid adoption of Acrobat are tailwinds.

Also, the company’s continued wins from key customers are contributing well. We remain optimistic about Adobe’s market position, compelling product lines, continued innovation, strong Creative Cloud adoption and strong Workfront momentum. However, ongoing tensions between Russia and Ukraine remain major headwinds for the digital media segment.

(You can read the full Adobe research report here >>>)

Shares of Bristol Myers outperformed the industry Zacks Medical – Biomedical and Genetics over the past year (+20% vs -27.7%). The Zacks analyst believes Eliquis’ strong performance and Opdivo’s accelerating growth. Eliquis is the leading oral anticoagulant drug and continues to experience market share growth. The extension of Opdivo’s label to lung cancer, kidney cancer and stomach cancer indications boosted sales. Revlimid continues to benefit from the demand for triple therapies and the increase in treatment duration.

New drug approvals add a new revenue stream, which should drive growth in the coming quarters. Pipeline progress has been impressive and strategic collaborations will further expand the portfolio. Equities have outperformed the industry over the year so far. However, Revlimid faces generic competition which will negatively impact sales. The competition is tough for Opdivo.

(You can read the full research report on Bristol-Myers here >>>)

Other noteworthy reports we feature today include BHP Group Ltd. and Micron Technology, Inc.

Note: Sheraz Mian leads the equity research department at Zacks and is a well-known expert on overall earnings. He is frequently quoted in the written and electronic press and publishes the weekly Earnings Trends and Earnings overview reports. If you would like to receive an email notification whenever Sheraz publishes a new article, please click here>>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. To visit for more information on the performance figures displayed in this press release.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 preferred stock to earn +100% or more in 2021. Previous recommendations have skyrocketed +143.0%, +175.9%, + 498.3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.